Eli Lilly & Co.

2Q Revenues: $4.6 billion (+14%)

2Q Earnings: $664 million (-19%)

YTD Revenues: $8.9 billion (+13%)

YTD Earnings: $1.2 billion (-29%)

Comments: Net income was impaired by the purchases of Hypnion and Ivy Animal Health. Cymbalta was the top gainer, with 2Q sales rising 67% to $520 million. Zyprexa sales grew 9% to $1.2 billion while #3 seller Gemzar posted sales of $396 million (+15%). R&D expenses rose 10% to $854 million.